South Korea’s Cha Bio, Israel’s Pluristem Swap Stock To Finance Stem Cell Research Deal
This article was originally published in PharmAsia News
Executive Summary
South Korea’s CHA Bio & Diostech has engaged in a $10.4 million share swap with Israel's Pluristem Therapeutics as part of a licensing partnership agreement reached in June.